Ark Biosciences

Shanghai, China Founded: 2014 • Age: 12 yrs
Chinese, clinical-stage biopharma developing small molecule therapeutics for respiratory viral infection and viral hepatitis
Annual revenue $3.3M Latest available
Total funding - 3 rounds
Employees - Tracked headcount
Investors 17 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Ark Biosciences

Ark Biosciences is a company based in Shanghai (China) founded in 2014. Ark Biosciences operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.

  • Headquarter Shanghai, China
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Ark Biosciences Private Limited
  • Date of Incorporation 19 Jul, 2006
  • Jurisdiction Mumbai, Maharashtra, India
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $3.31 M (USD)
    137.12
    as on Mar 31, 2020
  • Net Profit
    $615.91 K (USD)
    444.91
    as on Mar 31, 2020
  • EBITDA
    $609.31 K (USD)
    5800.07
    as on Mar 31, 2020
  • Latest Funding Round
    Not available
  • Investors
    TPG

    & 16 more

  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Ark Biosciences

Investors in Ark Biosciences

Ark Biosciences has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include TPG, Qiming Venture Partners and Visum Pharma.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Mid-market companies are targeted for investment by Loayal Valley Capital.
Locked Locked Locked
Venture capital investments are directed toward multiple sectors.
Locked Locked Locked
Private equity & venture capital firm
Locked Locked Locked
Premium access

Investor details for Ark Biosciences

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Ark Biosciences

Investments
Premium access

Investment portfolio details for Ark Biosciences

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Ark Biosciences

Premium access

Detailed financials for Ark Biosciences

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Ark Biosciences Comparisons

Ark Biosciences Primary company
Description
Chinese, clinical-stage biopharma developing small molecule ...
Location
Shanghai, China
Founded Year
2014
Annual Revenue
$3.31 M (USD)
Net Profit
$615.91 K (USD)
EBITDA
$609.31 K (USD)
Employees
Not available
Premium access

Peer comparison for Ark Biosciences

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Ark Biosciences

Ark Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
mRNA-based therapeutics for diseases including cancer and infections are developed.
Locked Locked Locked
Clinical diagnostics and drug discovery for immune diseases are provided.
Locked Locked Locked
Developer of novel protein-based therapeutics using machine learning and biological engineering
Locked Locked Locked
Developer of immunotherapies for the treatment of infectious diseases and cancer
Locked Locked Locked
Developer of biologics to treat hepatitis B infection
Locked Locked Locked
VBI Vaccines is engaged in developing vaccines and immunotherapeutics.
Premium access

Detailed competitors of Ark Biosciences

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Ark Biosciences

Premium access

Complete news archive for Ark Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ark Biosciences

Ark Biosciences was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Ark Biosciences is headquartered in Shanghai, China.

Annual revenue of Ark Biosciences is $3.31M as on Mar 31, 2020.

Ark Biosciences was founded in 2014 in Shanghai, China, as a clinical-stage biopharmaceutical company. Small molecule therapeutics targeting respiratory viral infections and viral hepatitis are developed by the firm. The lead candidate, AK0529, an oral inhibitor of RSV replication, has completed phase 1 trials and is advancing to phase 2. AK-612 for influenza remains in preclinical development, while two additional candidates address hepatitis B virus infections.

Ark Biosciences's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.

Ark Biosciences has 17 investors. Key investors include TPG, Qiming Venture Partners, Visum Pharma, Loayal Valley Capital, and Longda Food Group.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available